##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
 FORM 10-Q
 þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the Quarterly period ended July 31, 2010
 OR
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 Commission file number 0-17263
 CHAMPIONS BIOTECHNOLOGY, INC.
  Delaware
    
    52-1401755(State or other jurisdiction of incorporation or organization)
    
    (I.R.S. Employer Identification No.)855 N. Wolfe Street, Suite 619, Baltimore, MD
    
    21205(Address of principal executive offices)
    
    (zip code)
 (410) 369-0365  (Registrants telephone number, including area code)
 Inapplicable  (Former name, former address, and former fiscal year, if changed from last report)
 þ o
 Yes o No o
  Large accelerated filer o
    
    Accelerated filer o
    
    Non-Accelerated Filer o
    
    Smaller Reporting Company þ
 o þ




---



##### 



CHAMPIONS BIOTECHNOLOGY, INC.
FORM 10-Q
 INDEX
 PART I. Financial InformationItem 1. Financial StatementsCondensed Consolidated Balance Sheets as of July 31, 2010
(unaudited) and April 30, 2010
    
    
    3Condensed Consolidated Statements of Operations
for the three ended July 31, 2010 and 2009 (unaudited)
    
    
    4Condensed Consolidated Statements of Cash Flows for the
three months ended July 31, 2010 and 2009 (unaudited)
    
    
    5Notes to Condensed Consolidated Financial Statements (unaudited)
    
    
    6Item 2. Managements Discussion and Analysis of Financial Condition and
Results of Operations
    
    
    13Item 4. Controls and Procedures
    
    
    16PART II. Other InformationItem 1. Legal Proceedings
    
    
    17Item 1A. Risk Factors
    
    
    17Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
    
    
    17Item 3. Defaults Upon Senior Securities
    
    
    17Item 5. Other Information
    
    
    17Item 6. Exhibits
    
    
    17Signatures18Exhibit 31.1Exhibit 31.2Exhibit 32.1
   - 2 -




---



##### Table of Contents



PART I. FINANCIAL INFORMATION
 
 Item 1.
    
    Financial Statements
 CHAMPIONS BIOTECHNOLOGY, INC.
 
 CONDENSED CONSOLIDATED BALANCE SHEETS
 July 31, 2010
    
    
    April 30, 2010(unaudited)ASSETSCURRENT ASSETSCash and cash equivalents
    
    $
    2,088,000
    
    
    $
    2,572,000Accounts receivable
    
    
    33,000
    
    
    
    46,000Prepaid expenses, deposits, and other
    
    
    431,000
    
    
    
    540,000Total current assets
    
    
    2,552,000
    
    
    
    3,158,000Property and equipment, net
    
    
    115,000
    
    
    
    105,000Goodwill
    
    
    669,000
    
    
    
    669,000TOTAL ASSETS
    
    $
    3,336,000
    
    
    $
    3,932,000LIABILITIES AND STOCKHOLDERS EQUITYCURRENT LIABILITIESAccounts payable
    
    $
    1,109,000
    
    
    $
    944,000Accrued liabilities
    
    
    309,000
    
    
    
    236,000Deferred revenue
    
    
    555,000
    
    
    
    910,000Total current liabilities
    
    
    1,973,000
    
    
    
    2,090,000Other liabilities
    
    
    47,000
    
    
    
    77,000TOTAL LIABILITIES
    
    
    2,020,000
    
    
    
    2,167,000COMMITMENTS AND CONTINGENCIESAccrued stock purchase
    
    
    42,000
    
    
    
    188,000STOCKHOLDERS EQUITYPreferred stock, $10 par value; 56,075 shares authorized;
0 shares issued and outstanding
    
    
    
    
    
    
    Common stock, $.001 par value; 50,000,000 shares
authorized; 36,844,000 and 36,844,000 issued at July 31,
2010 and April 30, 2010, respectively, and 35,702,000
and 35,780,000 shares outstanding as of July 31, 2010
and April 30, 2010, respectively
    
    
    37,000
    
    
    
    37,000Treasury stock, at cost, 1,142,000 and 1,064,000 shares
at July 31, 2010 and April 30, 2010, respectively
    
    
    (250,000
    )
    
    
    (219,000
    )Stock subscription receivable
    
    
    (750,000
    )
    
    
    (750,000
    )Additional paid-in capital
    
    
    15,508,000
    
    
    
    15,193,000Accumulated deficit
    
    
    (13,271,000
    )
    
    
    (12,680,000
    )Accumulated other comprehensive income
    
    
    
    
    
    
    (4,000
    )Total stockholders equity
    
    
    1,274,000
    
    
    
    1,577,000TOTAL LIABILITIES AND STOCKHOLDERS EQUITY
    
    $
    3,336,000
    
    
    $
    3,932,000
   - 3 -




---



##### Table of Contents



CHAMPIONS BIOTECHNOLOGY, INC.
 
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
 (Unaudited)
 Three Months Ended July 31,2010
    
    
    2009OPERATING REVENUEPersonalized oncology services
    
    $
    1,109,000
    
    
    $
    899,000Preclinical eValuation services
    
    
    491,000
    
    
    
    63,000Total operating revenue
    
    
    1,600,000
    
    
    
    962,000COSTS AND OPERATING EXPENSESCost of Personalized oncology services
    
    
    324,000
    
    
    
    634,000Cost of Preclinical eValuation services
    
    
    222,000
    
    
    
    34,000Research and development
    
    
    919,000
    
    
    
    496,000General and administrative
    
    
    738,000
    
    
    
    806,000Total costs and operating expenses
    
    
    2,203,000
    
    
    
    1,970,000LOSS BEFORE OTHER INCOME
    
    
    (603,000
    )
    
    
    (1,008,000
    )Interest and other income
    
    
    12,000
    
    
    
    5,000LOSS BEFORE PROVISION FOR INCOME TAXES
    
    
    (591,000
    )
    
    
    (1,003,000
    )Provision for income taxes
    
    
    
    
    
    
    NET LOSS
    
    $
    (591,000
    )
    
    $
    (1,003,000
    )NET LOSS PER SHARE  BASIC AND DILUTED
    
    $
    (0.02
    )
    
    $
    (0.03
    )WEIGHTED AVERAGE SHARES OUTSTANDING 
BASIC AND DILUTED
    
    
    35,737,000
    
    
    
    32,757,000
   - 4 -




---



##### Table of Contents



CHAMPIONS BIOTECHNOLOGY, INC.
 
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 (Unaudited)
 Three Months Ended July 31,2010
    
    
    2009OPERATING ACTIVITIESNet loss
    
    $
    (591,000
    )
    
    $
    (1,003,000
    )Adjustments to reconcile net loss to net cash
used in operating activities:Stock-based compensation
    
    
    170,000
    
    
    
    50,000Depreciation
    
    
    10,000
    
    
    
    8,000Changes in operating assets and liabilities:Accounts receivable
    
    
    13,000
    
    
    
    Prepaid expenses, deposits, and other receivables
    
    
    109,000
    
    
    
    186,000Accounts payable
    
    
    165,000
    
    
    
    (1,000
    )Accrued liabilities and other
    
    
    43,000
    
    
    
    19,000Deferred revenue
    
    
    (355,000
    )
    
    
    (277,000
    )Net cash used in operating activities
    
    
    (436,000
    )
    
    
    (1,018,000
    )INVESTING ACTIVITIESPurchase of property and equipment
    
    
    (20,000
    )
    
    
    (44,000
    )Proceeds from certificate of deposit
    
    
    
    
    
    
    1,017,000Net cash (used in) provided by investing activities
    
    
    (20,000
    )
    
    
    973,000FINANCING ACTIVITIESPurchase of treasury stock
    
    
    (31,000
    )
    
    
    (156,000
    )Proceeds from exercise of options and warrants
    
    
    
    
    
    
    3,000Net cash used in financing activities
    
    
    (31,000
    )
    
    
    (153,000
    )Exchange rate effect on cash and cash equivalents
    
    
    3,000
    
    
    
    NET DECREASE IN CASH AND CASH EQUIVALENTS
    
    
    (484,000
    )
    
    
    (198,000
    )CASH AND CASH EQUIVALENTS  BEGINNING OF PERIOD
    
    
    2,572,000
    
    
    
    1,728,000CASH AND CASH EQUIVALENTS  END OF PERIOD
    
    $
    2,088,000
    
    
    $
    1,530,000
   - 5 -




---



##### Table of Contents



CHAMPIONS BIOTECHNOLOGY, INC.
 
 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 Note 1. Organization, Use of Estimates and Basis of Presentation
   Note 2. Summary of Significant Accounting Policies
 Unaudited Interim Financial Information
  Principles of Consolidation
   Segment Reporting
   - 6 -




---



##### Table of Contents



Use of Estimates
  Cash and Cash Equivalents
  Short-Term Investments
  Fair Value of Financial Instruments
  Goodwill
  Deferred Revenue
  Revenue Recognition
   - 7 -




---



##### Table of Contents



Cost of Personalized Oncology Services
  Cost of Preclinical eValuation Services
  Research and Development
  Recent Accounting Pronouncements
 Multiple-Deliverable Revenue Arrangements
 Note 3. Basic and Dilutive Loss Per Common Share
   - 8 -




---



##### Table of Contents



Three Months Ended July 31,2010
    
    
    2009Stock options
    
    
    650,385
    
    
    
    470,257Warrants
    
    
    462,273
    
    
    
    468,095Restricted stock
    
    
    2,974
    
    
    
    Total common stock equivalents
    
    
    1,115,632
    
    
    
    938,352
  Note 4. Property and Equipment
  July, 31
    
    
    April 30,2010
    
    
    2010Furniture and fixtures
    
    $
    6,000
    
    
    $
    6,000Computer equipment and software
    
    
    98,000
    
    
    
    42,000Laboratory equipment
    
    
    42,000
    
    
    
    37,000Software in-progress
    
    
    
    
    
    
    43,000Total property and equipment
    
    
    146,000
    
    
    
    128,000Less accumulated depreciation
    
    
    (31,000
    )
    
    
    (23,000
    )Property and equipment, net
    
    $
    115,000
    
    
    $
    105,000
  Note 5. Licensing Agreements
 Bithionol License Agreement
   TAR1 License Agreement
    - 9 -




---



##### Table of Contents



Benzoylyphenylerea License Agreement
  Liposome Option Agreement
  Note 6. Stock-Based Compensation
     Three Months Ended July 31,2010
    
    
    2009Cost of Personalized oncology services
    
    $
    
    
    
    $
    6,000Research and development
    
    
    22,000
    
    
    
    (12,000
    )General and administrative
    
    
    148,000
    
    
    
    56,000Total stock-based compensation expense
    
    $
    170,000
    
    
    $
    50,000
  Three Months Ended July 31,2010
    
    
    2009Expected term in years
    
    
    6.0
    
    
    
    6.0Risk-free interest rate
    
    
    2.0
    %
    
    
    3.0
    %Volatility
    
    
    104
    %
    
    
    94
    %Dividend yield
    
    
    0
    %
    
    
    0
    %
   - 10 -




---



##### Table of Contents



Stock Option Grants
   Warrants
   Note 7. Related Party Transactions
   Stock Repurchase Agreement
     - 11 -




---



##### Table of Contents



Note 8. Exit Costs
  Estimated
    
    
    Payments/
    
    
    AmountExpense
    
    
    Losses to Date
    
    
    RemainingSeverance payments
    
    $
    11,000
    
    
    $
    5,000
    
    
    $
    6,000Future lease payments, net of sublease rental
    
    
    18,000
    
    
    
    3,000
    
    
    
    15,000Moving costs and other
    
    
    7,000
    
    
    
    5,000
    
    
    
    2,000Disposal of assets
    
    
    22,000
    
    
    
    22,000
    
    
    
    Total
    
    $
    58,000
    
    
    $
    35,000
    
    
    $
    23,000
  Note 9. Research and Development Materials Purchase Agreement
  2011
    
    $
    297,0002012
    
    
    132,000Total payments
    
    $
    429,000
  - 12 -




---



##### Table of Contents



Item 2.
    
    Managements Discussion and Analysis of Financial Condition and Results of Operations.
 The following discussion of our historical results of operations and our liquidity and capital
resources should be read in conjunction with the financial statements and related notes that appear
elsewhere in this report.
 Forward-Looking Statements
 Managements Discussion and Analysis of
Financial Condition and Results of Operations
   Overview
    - 13 -




---



##### Table of Contents



Results of Operations
 Three Months Ended July 31, 2010 and 2009
 Operating Revenues:
  Costs and Operating Expenses:
       - 14 -




---



##### Table of Contents



Net Loss:
  Liquidity and Capital Resources
 Sources of Liquidity:
  Cash Flows:
  Three Months Ended July 31,2010
    
    
    2009Cash (used in) provided by:Operating activities
    
    $
    (436,000
    )
    
    $
    (1,018,000
    )Investing activities
    
    
    (20,000
    )
    
    
    973,000Financing activities
    
    
    (31,000
    )
    
    
    (153,000
    )Effect of exchange rates
    
    
    3,000
    
    
    
    Net decrease in cash and cash equivalents
    
    $
    (484,000
    )
    
    $
    (198,000
    )
      Commitments and Contractual Obligations
  Ability to Continue As a Going Concern
   - 15 -




---



##### Table of Contents



Off Balance Sheet Arrangements
  
 Item 4.
    
    Controls and Procedures
 Evaluation of Disclosure Controls and Procedures
  Changes in Internal Controls
   - 16 -




---



##### Table of Contents



PART II  OTHER INFORMATION
 
 Item 1.
    
    Legal Proceedings.
  
 Item 1A.
    
    Risk Factors
  
 Item 2.
    
    Unregistered Sales of Equity Securities and Use of Proceeds.
  Total Number ofShares Purchased
    
    
    Maximum NumberTotal
    
    
    Average
    
    
    as Part of
    
    
    of Shares that MayNumber of
    
    
    Price
    
    
    Publicly
    
    
    Yet Be PurchasedShares
    
    
    Paid per
    
    
    Announced Plans
    
    
    Under the Plans orPeriod
    
    Purchased
    
    
    Share
    
    
    or Programs
    
    
    ProgramsMay 2010
    
    
    77,962
    
    
    $
    0.40
    
    
    
    77,962
    
    
    
    1,603,831June 2010
    
    
    
    
    
    $
    0.00
    
    
    
    
    
    
    
    1,603,831July 2010
    
    
    
    
    
    $
    0.00
    
    
    
    
    
    
    
    1,603,831Total
    
    
    77,962
    
    
    $
    0.40
    
    
    
    77,962
    
    
    
    1,603,831
  
 Item 3.
    
    Defaults Upon Senior Securities.
  
 Item 5.
    
    Other Information
  
 Item 6.
    
    Exhibits
 Exhibit 31.1
    
    Certification by the Acting Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002Exhibit 31.2
    
    Certification by the Principal Financial Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002Exhibit 32.1
    
    Certification by the Acting Principal Executive Officer and
the Principal Financial Officer Pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
  - 17 -




---



##### Table of Contents



SIGNATURES
  CHAMPIONS BIOTECHNOLOGY, INC.
(Registrant)Date: September 10, 2010
    By:
    /s/ Mark R. SchonauMark R. SchonauChief Financial Officer  - 18 -